Telix Pharmaceuticals Statistics

Total Valuation

Telix Pharmaceuticals has a market cap or net worth of AUD 7.43 billion. The enterprise value is 7.33 billion.

Market Cap	7.43B
Enterprise Value	7.33B

Important Dates

The next estimated earnings date is Thursday, February 20, 2025.

Earnings Date	Feb 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Telix Pharmaceuticals has 334.68 million shares outstanding. The number of shares has increased by 5.90% in one year.

Current Share Class	n/a
Shares Outstanding	334.68M
Shares Change (YoY)	+5.90%
Shares Change (QoQ)	+4.39%
Owned by Insiders (%)	15.52%
Owned by Institutions (%)	23.74%
Float	282.73M

Valuation Ratios

The trailing PE ratio is 150.93 and the forward PE ratio is 87.37.

PE Ratio	150.93
Forward PE	87.37
PS Ratio	11.15
PB Ratio	18.37
P/TBV Ratio	n/a
P/FCF Ratio	193.76
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 98.30, with an EV/FCF ratio of 191.23.

EV / Earnings	149.10
EV / Sales	11.36
EV / EBITDA	98.30
EV / EBIT	108.88
EV / FCF	191.23

Financial Position

The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.05.

Current Ratio	0.99
Quick Ratio	0.81
Debt / Equity	0.05
Debt / EBITDA	0.30
Debt / FCF	0.58
Interest Coverage	75.00

Financial Efficiency

Return on equity (ROE) is 20.49% and return on invested capital (ROIC) is 16.34%.

Return on Equity (ROE)	20.49%
Return on Assets (ROA)	7.97%
Return on Capital (ROIC)	16.34%
Revenue Per Employee	1.53M
Profits Per Employee	116,277
Employee Count	234
Asset Turnover	1.22
Inventory Turnover	11.07

Taxes

Income Tax	-2.12M
Effective Tax Rate	-68.80%

Stock Price Statistics

The stock price has increased by +143.15% in the last 52 weeks. The beta is 2.40, so Telix Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	2.40
52-Week Price Change	+143.15%
50-Day Moving Average	21.62
200-Day Moving Average	17.42
Relative Strength Index (RSI)	48.64
Average Volume (20 Days)	1,158,968

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Telix Pharmaceuticals had revenue of AUD 645.68 million and earned 49.19 million in profits. Earnings per share was 0.15.

Revenue	645.68M
Gross Profit	405.35M
Operating Income	67.35M
Pretax Income	50.07M
Net Income	49.19M
EBITDA	73.14M
EBIT	67.35M
Earnings Per Share (EPS)	0.15

Full Income Statement

Balance Sheet

The company has 118.84 million in cash and 22.14 million in debt, giving a net cash position of 96.69 million or 0.29 per share.

Cash & Cash Equivalents	118.84M
Total Debt	22.14M
Net Cash	96.69M
Net Cash Per Share	0.29
Equity (Book Value)	403.97M
Book Value Per Share	1.21
Working Capital	-3.11M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 49.71 million and capital expenditures -11.36 million, giving a free cash flow of 38.35 million.

Operating Cash Flow	49.71M
Capital Expenditures	-11.36M
Free Cash Flow	38.35M
FCF Per Share	0.11

Full Cash Flow Statement

Margins

Gross margin is 62.78%, with operating and profit margins of 10.43% and 7.62%.

Gross Margin	62.78%
Operating Margin	10.43%
Pretax Margin	7.75%
Profit Margin	7.62%
EBITDA Margin	11.33%
EBIT Margin	10.43%
FCF Margin	5.94%

Dividends & Yields

Telix Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.90%
Shareholder Yield	-5.90%
Earnings Yield	0.66%
FCF Yield	0.52%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Telix Pharmaceuticals has an Altman Z-Score of 7.5 and a Piotroski F-Score of 6.

Altman Z-Score	7.5
Piotroski F-Score	6